logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Search...
search
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Latest

Goldman Sachs: Slightly lowers China Soft International (00354.HK) target price to HK$3, maintains "Sell" rating.

date
20/10/2026
Zhito Finance APP has learned that Goldman Sachs issued a research report stating that it has lowered the target price for China Software International (00354.HK) from HK$3.1 to HK$3, maintained its "Sell" rating, and raised its net profit forecasts for 2026 to 2028 by 19%, 11%, and 13%, respectively.
Latest
3 m ago
Industrial Bank Holdings (00132.HK) subsidiary enters into finance lease with Zhenlai County Rongxiang Thermal Power
3 m ago
Lenovo Technology (02436.HK) spent HKD 109,000 to repurchase 5,400 shares on October 20.
4 m ago
Yunzhongma (603130.SH) released its performance for the first three quarters, with net profit attributable to the parent company of 77.57 million yuan, a year-on-year increase of 53.66%.
5 m ago
Sihuan Pharmaceutical (00460.HK): The injectable polycaprolactone microsphere facial filler and the injectable sodium hyaluronate composite solution independently developed by Meiyan Space have been approved for marketing in Hong Kong.
6 m ago
Wolwo Bio-Pharmaceutical (300357.SZ): Clinical trial application for S01D tablets approved
See all latestmore
logo
Contact US
qr
+852 - 60190728
[email protected]
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2026 GMT EIGHT Holdings. All Rights Reserved.